170 related articles for article (PubMed ID: 14638467)
1. Effects of DQ-113, a new quinolone, against methicillin- and vancomycin-resistant Staphylococcus aureus-caused hematogenous pulmonary infections in mice.
Kaneko Y; Yanagihara K; Miyazaki Y; Tsukamoto K; Hirakata Y; Tomono K; Kadota J; Tashiro T; Murata I; Kohno S
Antimicrob Agents Chemother; 2003 Dec; 47(12):3694-8. PubMed ID: 14638467
[TBL] [Abstract][Full Text] [Related]
2. Potency of DX-619, a novel des-F(6)-quinolone, in haematogenous murine bronchopneumonia caused by methicillin-resistant and vancomycin-intermediate Staphylococcus aureus.
Yanagihara K; Seki M; Izumikawa K; Higashiyama Y; Miyazaki Y; Hirakata Y; Tomono K; Mizuta Y; Tsukamoto K; Kohno S
Int J Antimicrob Agents; 2006 Sep; 28(3):212-6. PubMed ID: 16887340
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of ME1036 against meticillin-resistant Staphylococcus aureus and vancomycin-insensitive S. aureus in a model of haematogenous pulmonary infection.
Yanagihara K; Ohnishi Y; Morinaga Y; Nakamura S; Kurihara S; Seki M; Izumikawa K; Kakeya H; Yamamoto Y; Yamada Y; Kohno S; Kamihira S
Int J Antimicrob Agents; 2008 Nov; 32(5):401-4. PubMed ID: 18715761
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of quinupristin-dalfopristin against methicillin-resistant Staphylococcus aureus and vancomycin-insensitive S. aureus in a model of hematogenous pulmonary infection.
Yanagihara K; Okada M; Fukuda Y; Imamura Y; Kaneko Y; Ohno H; Higashiyama Y; Miyazaki Y; Tsukamoto K; Hirakata Y; Tomono K; Kadota J; Tashiro T; Murata I; Kohno S
Chemotherapy; 2004 Nov; 50(5):260-4. PubMed ID: 15528893
[TBL] [Abstract][Full Text] [Related]
5. [Combined effect of vancomycin or teicoplanin plus a beta-lactam antibiotic in mouse infection models caused by beta-lactam antibiotec-induced vancomycin resistant MRSA (BIVR)].
Hatano K; Yokota Y; Hanaki H; Sunakawa K
Kansenshogaku Zasshi; 2006 May; 80(3):243-50. PubMed ID: 16780131
[TBL] [Abstract][Full Text] [Related]
6. Potency of SMP-601, a novel carbapenem, in hematogenous murine bronchopneumonia caused by methicillin-resistant and vancomycin-intermediate Staphylococcus aureus.
Kihara R; Yanagihara K; Morinaga Y; Araki N; Nakamura S; Seki M; Izumikawa K; Kakeya H; Yamamoto Y; Tsukamoto K; Kamihira S; Kohno S
Antimicrob Agents Chemother; 2008 Jun; 52(6):2163-8. PubMed ID: 18391033
[TBL] [Abstract][Full Text] [Related]
7. In vitro combined effects of cefozopran/teicoplanin and cefozopran/vancomycin on methicillin-resistant Staphylococcus aureus.
Toyokawa M; Asari S; Nishi I; Horikawa M; Tsukamoto H; Sunada A; Ueda A; Iwatani Y
J Chemother; 2003 Feb; 15(1):31-6. PubMed ID: 12678411
[TBL] [Abstract][Full Text] [Related]
8. Comparative activity of tedizolid and glycopeptide combination therapies for the treatment of Staphylococcus aureus infections: an in vitro and in vivo evaluation against strains with reduced susceptibility to glycopeptides.
Betts JW; Abdul Momin HF; Phee LM; Wareham DW
J Med Microbiol; 2018 Feb; 67(2):265-271. PubMed ID: 29300156
[TBL] [Abstract][Full Text] [Related]
9. Pharmacodynamic activity of ceftobiprole compared with vancomycin versus methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-intermediate Staphylococcus aureus (VISA) and vancomycin-resistant Staphylococcus aureus (VRSA) using an in vitro model.
Zhanel GG; Voth D; Nichol K; Karlowsky JA; Noreddin AM; Hoban DJ
J Antimicrob Chemother; 2009 Aug; 64(2):364-9. PubMed ID: 19454524
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of linezolid against methicillin-resistant or vancomycin-insensitive Staphylococcus aureus in a model of hematogenous pulmonary infection.
Yanagihara K; Kaneko Y; Sawai T; Miyazaki Y; Tsukamoto K; Hirakata Y; Tomono K; Kadota J; Tashiro T; Murata I; Kohno S
Antimicrob Agents Chemother; 2002 Oct; 46(10):3288-91. PubMed ID: 12234863
[TBL] [Abstract][Full Text] [Related]
11. Comparison of sparfloxacin, temafloxacin, and ciprofloxacin for prophylaxis and treatment of experimental foreign-body infection by methicillin-resistant Staphylococcus aureus.
Cagni A; Chuard C; Vaudaux PE; Schrenzel J; Lew DP
Antimicrob Agents Chemother; 1995 Aug; 39(8):1655-60. PubMed ID: 7486895
[TBL] [Abstract][Full Text] [Related]
12. In vivo efficacy of a new quinolone, DQ-113, against Streptococcus pneumoniae in a mouse model.
Otsu Y; Yanagihara K; Fukuda Y; Miyazaki Y; Tsukamoto K; Hirakata Y; Tomono K; Kadota J; Tashiro T; Murata I; Kohno S
Antimicrob Agents Chemother; 2003 Dec; 47(12):3699-703. PubMed ID: 14638468
[TBL] [Abstract][Full Text] [Related]
13. [Combination effect between panipenem and vancomycin on highly methicillin-resistant Staphylococcus aureus].
Fukuoka T; Domon H; Kakuta M; Ishii C; Hirasawa A; Utsui Y; Ohya S; Yasuda H
Jpn J Antibiot; 1997 Apr; 50(4):411-9. PubMed ID: 9192249
[TBL] [Abstract][Full Text] [Related]
14. [Reliability of disc-diffusion susceptibility testing for arbekacin, vancomycin and teicoplanin against methicillin-resistant Staphylococcus aureus].
Kouda M; Homma S; Udagawa I; Tamura K; Fukuhara J; Takeuchi M
Jpn J Antibiot; 1999 Dec; 52(12):681-9. PubMed ID: 10695023
[TBL] [Abstract][Full Text] [Related]
15. Teicoplanin alone or combined with rifampin compared with vancomycin for prophylaxis and treatment of experimental foreign body infection by methicillin-resistant Staphylococcus aureus.
Schaad HJ; Chuard C; Vaudaux P; Waldvogel FA; Lew DP
Antimicrob Agents Chemother; 1994 Aug; 38(8):1703-10. PubMed ID: 7985998
[TBL] [Abstract][Full Text] [Related]
16. Emergence of vancomycin resistant Staphylococcus aureus (VRSA) from a tertiary care hospital from northern part of India.
Tiwari HK; Sen MR
BMC Infect Dis; 2006 Oct; 6():156. PubMed ID: 17067393
[TBL] [Abstract][Full Text] [Related]
17. Methicillin-resistant Staphylococcus aureus heterogeneously resistant to vancomycin in a Turkish university hospital.
Sancak B; Ercis S; Menemenlioglu D; Colakoglu S; Hasçelik G
J Antimicrob Chemother; 2005 Sep; 56(3):519-23. PubMed ID: 16046461
[TBL] [Abstract][Full Text] [Related]
18. Relevance of vancomycin-intermediate susceptibility and heteroresistance in methicillin-resistant Staphylococcus aureus bacteraemia.
Khatib R; Jose J; Musta A; Sharma M; Fakih MG; Johnson LB; Riederer K; Shemes S
J Antimicrob Chemother; 2011 Jul; 66(7):1594-9. PubMed ID: 21525024
[TBL] [Abstract][Full Text] [Related]
19. [Evaluation of the activity and effects of combinations of various antibacterial agents against methicillin-resistant Staphylococcus aureus in vitro].
Kouda M; Homma S; Udagawa I; Fukuhara J; Takeuchi M; Tamura K
Jpn J Antibiot; 2000 Mar; 53(3):171-8. PubMed ID: 10834148
[TBL] [Abstract][Full Text] [Related]
20. [Effect of arbekacin on the production of toxic shock syndrome toxin 1 by methicillin-resistant Staphylococcus aureus].
Miyata A; Araake M; Ogawa H; Hanaki H; Hiramatsu K
Jpn J Antibiot; 2001 Jul; 54(7):372-81. PubMed ID: 11560056
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
